Xenon | Jotup

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on:

Thursday, March 28, 2024

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points:

Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

Retrieved on:

Tuesday, March 5, 2024

Xenon, Conference

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.

Key Points:

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.
Company Fireside Chat Presentation Details:

Japanese Studio 'Cocone' Launches AlterEgo City on iOS and Android

Retrieved on:

Thursday, March 7, 2024

Xenon, Friends, IOS, App Store (iOS/iPadOS), Google Play, Social, Music, Android, Centennial, AlterEgo, Video game

NEW YORK, March 7, 2024 /PRNewswire/ -- Cocone, a leading Japanese immersive entertainment studio at the forefront of avatar and digital fashion creation, today announced the launch of AlterEgo City (formerly known as Centennial and AlterEgo City), a unique digital experience at the intersection of art, fashion, and music, now available on iOS and Android devices via the Apple App Store and Google Play. The launch of AlterEgo City represents the first major games release from Cocone in the US market, and stands as a testament to the company's work in digital avatar creation.

Key Points:

The launch of AlterEgo City represents the first major games release from Cocone in the US market, and stands as a testament to the company's work in digital avatar creation.
AlterEgo City transports players to the visually stunning and bustling world of Centennial, an immersive experience that offers them the chance to customize and design their own unique digital avatar.
AlterEgo City also offers players the chance to produce their own music, with the ability to develop custom tracks that can be heard through the player's AlterEgo.
For more information about AlterEgo City, including how to download the game for iOS and Android devices, please visit https://www.alter-ego.city/

JCB partners with FrenchSys to boost card acceptance across France

Retrieved on:

Tuesday, November 28, 2023

JCB Co., Ltd., Partnership, PIN, Certification, News, Level 3, JCB, CBI, Growth, Xenon, Online shopping

Tokyo, London, Paris, Nov 28, 2023 - (JCN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd. (JCB), announced its partnership with FrenchSys, a subsidiary of CB-Investissements (CBI), to facilitate a greater JCB certification process for payment terminals across France.

Key Points:

Tokyo, London, Paris, Nov 28, 2023 - (JCN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd. (JCB), announced its partnership with FrenchSys, a subsidiary of CB-Investissements (CBI), to facilitate a greater JCB certification process for payment terminals across France.
This alliance helps banks, terminal manufacturers, and merchant partners to accept JCB Cards through an integrated certification process, hosted by FrenchSys.
This development will allow our valuable cardmembers to use their JCB Cards more widely throughout France, which is fantastic news for them and the merchant partners who serve them.
Cedric Sarazin, Managing Director, FrenchSys, added: "FrenchSys was established in 2019 to facilitate the acceptance of multi-scheme payments in France, serving acquirers, card schemes, manufacturers, and digital payment processors.

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on:

Monday, December 4, 2023

Xenon, Telephone, Suite, Montgomery Street, Sale, Jefferies Group, Attention, Jefferies, RBC Capital Markets, BofA Securities, Vesey Street, Prospectus, Madison Avenue, Equity capital markets, Exercise, Security (finance)

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.

Key Points:

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.
The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $345.0 million.
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets acted as joint book-running managers for the offering.
The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

Retrieved on:

Saturday, December 2, 2023

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).

Key Points:

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).
Importantly, we are looking forward to presenting new interim data from our ongoing open-label extension study from our Phase 2b X-TOLE trial.
The exhibit will also feature the topline results from the Phase 2 proof-of-concept X-NOVA clinical trial in major depressive disorder.
Posters will be added to the Xenon website consistent with AES 2023 conference guidelines.

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

Retrieved on:

Thursday, November 30, 2023

Xenon, Telephone, Suite, Montgomery Street, Sale, Jefferies Group, Attention, Jefferies, RBC Capital Markets, BofA Securities, Vesey Street, Prospectus, Madison Avenue, Broadridge Financial Solutions, Equity capital markets, Security (finance)

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.

Key Points:

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.
In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,384,615 common shares at the public offering price, less the underwriting discounts and commissions.
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.
These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering.

Xenon Pharmaceuticals Announces Proposed Public Offering

Retrieved on:

Wednesday, November 29, 2023

All of the common shares and pre-funded warrants in this offering are being offered by Xenon.

Key Points:

All of the common shares and pre-funded warrants in this offering are being offered by Xenon.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets are acting as joint book-running managers for the proposed offering.
An automatically effective shelf registration statement relating to the securities offered in the proposed public offering described above was filed with the Securities and Exchange Commission (SEC) on October 4, 2021.

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

Retrieved on:

Monday, November 27, 2023

Xenon, Șaeș, Physician, Anhedonia, Depression, Epilepsy, American Epilepsy Society, DSM-IV codes, Incidence, SAE, Seizure, Clinical Global Impression, Neurology, Weight gain, MDD, Patient, Safety, Pharmaceutical industry

The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.

Key Points:

The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.
The mean reduction was 13.90 in the placebo group, 15.61 in the XEN1101 10 mg group and 16.94 in the XEN1101 20 mg group.
A clear dose response and a clinically meaningful, but not statistically significant, 3.04 difference between placebo and the XEN1101 20 mg group (p=0.135) was observed.
We are excited to share the data generated in X-NOVA with epileptologists and neurologists at the upcoming American Epilepsy Society meeting in December.”

Glaring opportunity: How Nissan is countering a headlight dilemma

Retrieved on:

Thursday, December 21, 2023

The increased illumination of LED (light-emitting diode) headlights creates a dilemma: It allows drivers to see more clearly ahead, but can cause additional glare for drivers in the oncoming lane. This has led to growing frustrations for nighttime drivers -- especially during the dark winter months. With more than 90% of accidents caused by human error, Nissan is enhancing headlight technology as part of its mission to protect people and help drivers avoid risky situations. (Graphic: Business Wire)

Key Points:

With more than 90% of accidents caused by human error, Nissan is enhancing headlight technology as part of its mission to protect people and help drivers avoid risky situations.
(Graphic: Business Wire)
With more than 90% of accidents caused by human error, Nissan is enhancing headlight technology as part of its mission to protect people and help drivers avoid risky situations .
Brad Chisholm is an engineer on the exterior Lights, Mirrors and Wipers team at Nissan Technical Center North America in Farmington Hills, Michigan.
Achieving these results is an enormous effort – Chisholm says a Nissan headlight typically undergoes at least 300 tests before it is approved for production.